Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Biomarin Pharmaceutical Q2 2024 Adj EPS $0.96 Beats $0.35 Estimate, Sales $712.03M Beat $662.05M Estimate

Author: Benzinga Newsdesk | August 05, 2024 04:13pm
Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.35 by 174.29 percent. The company reported quarterly sales of $712.03 million which beat the analyst consensus estimate of $662.05 million by 7.55 percent. This is a 19.61 percent increase over sales of $595.27 million the same period last year.

Posted In: BMRN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist